mounjaro tirzepatide approvazione italia 💊Mounjaro® uno nuovo trattamento farmacologico

Tirzepatide is a dual glucosedependent insulinotropic polypeptide (GIP) and glucagonlike peptide1 (GLP1) receptor agonist that has shown greater weight loss and broad metabolic effects in type 2 diabetes and obesity than earlier incretinbased therapies [8]

If your vial is 60 mg/mL, you should be working with very small unit amounts

Start Your Weight Loss Journey With The Leading GLP-1 Weight Loss Clinic

Every time the concentration doubles, the milligram dose delivered by 50 units also doubles

For constipation, increase water intake substantially, add fiber gradually (too much too fast worsens problems), consider a gentle stool softener, and ensure youre eating adequate food despite reduced appetite